Abstract: In both cases, a “control ADC” with known toxicity against the same target is required to serve as positive control for the assessment of the potency of the new ADC.Summary: Once an antibody is en route as a candidate for antibody-drug conjugate (ADC) development, it is crucial to select suitable payload-linker complexes for ADC formulation and in the meantime, to develop assays that demonstrate the toxicity of the newly formed ADC.References: https://www.creative-biolabs.com/resource/adc/pdf/com/flyers/20180919-Control-ADC-for-R-D.pdf
Ask the author a question about this poster.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Active lifestyle and cognitive performance in older adults
Hana Georgi, Zuzana Frydrychová
Improving the Chemical Synthesis and Performance of Extended-Length Guide RNAs for Genome Editing and Control of Gene Expression
Laurakay Bruhn, Bo Curry, Rob Kaiser, Ben Lunstad, Ryan McCaffrey, Joel Myerson, Subhadeep Roy, Daniel Ryan, Israel Steinfeld, David Taussig, Justin Townsend, Suhani Thakker, Doug Dellinger
Modulating the Activity of CRISPR-Cas with Chemical Modifications in Single-Guide RNAs
Daniel Ryan, David Taussig, Suhani Thakker, Israel Steinfeld, Ben Lunstad, Rob Kaiser, Ryan McCaffrey, Justin Townsend, Patrick Chaffey, Bo Curry, Doug Dellinger, Laurakay Bruhn
Probiocs Related Products at Creative Enzymes
Virus-like Particles Based Vaccine Development